The FY19 LCRP Idea Development Award mechanism promotes new ideas that are still in the early stages of Development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. Applications should include a well- formulated, testable hypothesis based on strong scientific rationale. Submissions from and partnerships with investigators at Department of Defense (DoD) military treatment facilities and laboratories, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged
This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.
The purpose of this project is to identify skin physiology characteristics that differ between healthy and skin disease population groups and incorporate them into dermal physiologically-based pharmacokinetic models to improve their predictability. The models developed will be utilized to perform virtual bioequivalence assessments between brand name and generic drug products to inform regulatory decisions relating to the development of generic topical dermatological drug products and transdermal delivery systems.
This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies and blood biospecimens utilized as liquid biopsies. Extramural research funded under this FOA may include investigations of preanalytical variability relevant to diagnostic associated with the procurement and study of small biopsies (core biopsies, small excision samples), pleural aspirates, and blood utilized for liquid biopsies. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.
The FY19 KCRP Idea Development Award is intended to support innovative ideas and high-impact approaches, based on scientifically sound evidence, to move toward the KCRP vision of eliminating kidney cancer. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. Personnel on the proposed team should have a strong background in kidney cancer research.
The BMFRP Idea Development Award is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the BMFRP vision of understanding and curing BMF diseases. This award mechanism is designed to support new ideas. Proposed research studies should have a high probability of revealing new avenues of investigation. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach. Personnel on the proposed team should have a strong background in BMF disease research.
The KCRP Technology Development Award is a product-driven award mechanism intended to advance the Development of technologies to aid kidney cancer clinical and patient outcomes, including prevention, detection, diagnosis, treatment, or quality of life. Applicants with limited kidney cancer experience are strongly encouraged to collaborate with those having substantial expertise in kidney cancer research and/or kidney cancer model systems. Applications must describe how the technology will enhance the existing knowledge of kidney cancer.
The FY20 LCRP Idea Development Award mechanism promotes new ideas that are still in the early stages of Development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. Applications should include a well- formulated, testable hypothesis based on strong scientific rationale. Submissions from and partnerships with investigators at Department of Defense (DoD) military treatment facilities and laboratories, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged.
Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PI's research and career development. It should be clear that the proposed research is intellectually designed by the PI and not a product of the Designated Mentor. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.Key elements of the Career development Award mechanism are as follows:* Principal Investigator: The PI must be an independent, early-career researcher or physician-scientist within 10 years after completion of his/her terminal degree (excluding time spent in residency or on family medical leave). Time spent as a postdoctoral fellow is not excluded.
Applications to the Fiscal Year 2017 (FY17) Peer Reviewed Cancer Research Program (PRCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The PRCRP was initiated in 2009 to provide support for research of exceptional scientific merit and is managed by the CDMRP. Appropriations for the PRCRP from FY09 through FY16 totaled $199.8 million (M). The FY17 appropriation is $60M.
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support institutional career development programs in urological research that will assist MDs, PhDs, and MD/PhDs with an interest in benign urological disease or urological research to develop the skills necessary to initiate and sustain an independent research career in urological research. Research areas supported by this initiative must be related to the mission of the NIDDK (http://www2.niddk.nih.gov/Research/ScientificAreas/Urology/)
The Medical Research Fellows Program enables students to be immersed in a high-impact, intensive research experience at a critical time in their professional education, before they make plans for residency or postdoctoral training. Unique aspects of the program include national and regional professional development activities, mentorship by physician-scientists, interaction with HHMI investigators, and integration into a community of like-minded peers.
Each student selects and works with a mentor to develop a basic, translational, or applied biomedical research proposal. Both mentor selection and the research proposal are key components of the fellowship application; working with an HHMI scientist is encouraged but not required. Mentors can be at any academic or nonprofit research institution in the United States (excluding the National Institutes of Health and any other government agency) or at HHMI's Janelia Research Campus in Ashburn, VA.
The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes the ability to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.
FOA Emphasis. The FOA utilizes the R33 mechanism which is suitable for projects where proof-of-principle of the proposed technology or methodology has been demonstrated and supportive preliminary data are available. Proposed projects should offer new tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" r "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.
The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career Development experience in the fields of biomedical and behavioral research, including translational research.
The National Cancer Institute (NCI) Exploratory/Developmental Grant (R21) funding opportunity supports the Development of new research activities in all areas of cancer research. The R21 mechanism is intended to encourage exploratory and Developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the Development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).
he Idea Development Award promotes new ideas that are still in the early stages of Development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths from lung cancer. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.
The purpose of the Initiative for Maximizing Student Development (IMSD) Program is to develop the pool of a diverse group of highly trained undergraduate and graduate students who go on to research careers and will be available to participate in NIH-funded research. The program provides institutional grants to research-intensive institutions that propose well-integrated Developmental activities designed to increase students' academic preparation and skills that are critical to the completion of the Ph.D. degree in biomedical and behavioral sciences.
The OCRP Ovarian Cancer Academy, which was initially created in FY09, is intended to be a unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty. The overarching goal of the Ovarian Cancer Academy is to develop successful, highly productive ovarian cancer researchers in a collaborative research training environment. The current Ovarian Cancer Academy is a virtual career development and research training platform consisting of nine Early-Career Investigator/Designated Mentor pairs from different institutions and one Academy Dean. The Academy Dean serves as a resource for the Early-Career Investigators and Mentors, assesses the progress of the Early-Career Investigators, and facilitates communication and collaboration among all of the Early-Career Investigators and Mentors.
